Multiomics News and Research

RSS

UC San Diego receives funding to establish the Polysubstance Addiction Research Center

Researchers from University of California San Diego have received a $12.6 million award from the National Institute on Drug Abuse (NIDA) to establish the Polysubstance Addiction Research Center (PARC), a multidisciplinary center designed to uncover the biological factors that contribute to addiction across multiple substances.

30 Sep 2026

New framework maps the complex link between psychological status and cardiovascular health

CVD remains the leading cause of death worldwide, while the global burden of mental disorders continues to rise.

28 Sep 2026

Astoriom acquires additional UK storage business to expand capacity and service offerings

Astoriom, a global leader in scientific research and consumer product sample stability and biorepository storage, has acquired Roylance Stability Storage Limited and Roylance Scientific Limited, the UK operations of life sciences stability storage provider Sampled, located in Glasgow.

From Astoriom 25 Sep 2026

Regular exercisers show distinct metabolic and immune signatures in blood

Researchers compared blood samples from 40 regular exercisers and 46 sedentary adults and found differences in metabolites, blood chemistry, and immune cell gene activity. The patterns suggested greater fatty acid use and altered immune signaling among exercisers, but the study could not establish that exercise caused these differences.

21 Sep 2026

Bacterial extracellular vesicles show potential for cancer diagnosis and treatment

Bacteria shed membrane-enclosed tiny particles filled with proteins, lipids, DNA, RNA and metabolites. These particles, commonly known as bacterial extracellular vesicles (BEVs), are now being explored as possible tools for cancer diagnosis and treatment.

13 Aug 2026

Novogene Europe expands single-cell sequencing capability at Cambridge Omics Centre

Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre.

From Novogene Europe 27 Jul 2026

Researchers link genome folding to gene activity and brain tissue organization in Alzheimer's

Researchers from Carnegie Mellon University's School of Computer Science, the University of Pittsburgh School of Medicine and the University of Washington shed new light on Alzheimer's disease that could point to new directions for treatment.

23 Jul 2026

New bacterial control strategy helps revive failing last-line antibiotics

Antimicrobial resistance is one of the world's most alarming public health challenges, because the multidrug-resistant (MDR) gram-negative bacteria increasingly render even last-line antibiotics ineffective, leading to substantially higher mortality rates.

23 Jul 2026

Novogene Europe launches Untargeted Metabolomics Service at Cambridge Omics Centre

Novogene Europe, a multiomics research services partner, today announced that it has strengthened its position as a multiomics partner with the launch of its Untargeted Metabolomics Service through its Cambridge Omics Centre.

From Novogene Europe 13 Jul 2026

Biognosys showcases next-gen multiomics innovations at ASMS 2026

The Biognosys Group, a leader in mass spectrometry-based multiomics, announces advancements across its integrated multiomics portfolio, highlighting next-generation software, sample preparation, enrichment, and separation technologies for proteomics and metabolomics.

From Biognosys 26 Jun 2026

Scientists find link between bacterium in the gut ecosystem and lupus

Scientists at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, found a link between a bacterium in the gut microbiome, or ecosystem, and lupus, which could lead to more effective treatment of the disease, in a study published in Nature Communications.

25 Jun 2026

Glucosamine may worsen Alzheimer’s by fueling abnormal brain glycosylation

A Nature Metabolism study identifies brain hyperglycosylation as a metabolic driver of Alzheimer’s disease, with increased N-glycan biosynthesis seen in human AD tissue and mouse models. Reducing glycosylation improved memory in AD mice, while glucosamine worsened memory deficits in 5xFAD mice and was associated with poorer outcomes in dementia patients.

14 Jun 2026

ELRIG unveils keynote speakers for Drug Discovery 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speaker program for Drug Discovery 2026.

From ELRIG (UK) Ltd. 3 Jun 2026

Lab-grown brain models reveal how epilepsy drug alters fetal development

It is known that the antiepileptic drug valproate increases the risk of developmental disorders in unborn children.

22 May 2026

Medical imaging could improve precision diagnosis of aggressive head and neck tumors

Medical imaging routinely used in cancer care may hold far more biological information than previously thought.

13 May 2026

Largest blood protein genetics study reveals new precision medicine opportunities

Involving a collaboration with 118 investigators contributing from 89 institutions, scientists from Queen Mary University of London's Precision Healthcare University Research Institute and Berlin Institute of Health (BIH) at Charité have led the world's largest study on the genetic regulation of blood proteins.

6 May 2026

New immune mapping tool reveals how lung cancer reshapes immune cells

Researchers at VIB and VUB have developed a powerful new way to study how the immune system behaves inside lung tumors.

27 Apr 2026

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a therapeutic effect on rheumatoid arthritis (RA) by promoting the degradation of acyl coenzyme A thioesterase 1 (ACOT1) via the ubiquitin‒proteasome pathway and restoring the homeostasis of unsaturated fatty acids.

25 Apr 2026

Bacterial vesicles emerge as powerful tools against antibiotic resistance

Antibiotic resistance is making bacterial infections harder to treat, demanding new therapeutic strategies. A new review highlights bacterial extracellular vesicles (BEVs) as promising nanoscale tools that can kill pathogens, block infection, enhance vaccines, and deliver drugs.